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A Metalloproteinase Mirolysin of Tannerella forsythia Inhibits
All Pathways of the Complement System
Monika Jusko,* Jan Potempa,†,‡ Danuta Mizgalska,† Ewa Bielecka,*,† Miroslaw Ksiazek,†
Kristian Riesbeck,x Peter Garred,{ Sigrun Eick,‖ and Anna M. Blom*
Recent reports focusing on virulence factors of periodontal pathogens implicated proteinases as major determinants of remarkable
pathogenicity of these species, with special emphasis on their capacity to modulate complement activity. In particular, bacteria-
mediated cleavage of C5 and subsequent release of C5a seems to be an important phenomenon in the manipulation of the local
inflammatory response in periodontitis. In this study, we present mirolysin, a novel metalloproteinase secreted by Tannerella
forsythia, a well-recognized pathogen strongly associated with periodontitis. Mirolysin exhibited a strong effect on all complement
pathways. It inhibited the classical and lectin complement pathways due to efficient degradation of mannose-binding lectin, ficolin-2,
ficolin-3, and C4, whereas inhibition of the alternative pathway was caused by degradation of C5. This specificity toward
complement largely resembled the activity of a previously characterized metalloproteinase of T. forsythia, karilysin. Interestingly,
mirolysin released the biologically active C5a peptide in human plasma and induced migration of neutrophils. Importantly, we
demonstrated that combination of mirolysin with karilysin, as well as a cysteine proteinase of another periodontal pathogen,
Prevotella intermedia, resulted in a strong synergistic effect on complement. Furthermore, mutant strains of T. forsythia, devoid of
either mirolysin or karilysin, showed diminished survival in human serum, providing further evidence for the synergistic inac-
tivation of complement by these metalloproteinases. Taken together, our findings on interactions of mirolysin with complement
significantly add to the understanding of immune evasion strategies of T. forsythia and expand the knowledge on molecular
mechanisms driving pathogenic events in the infected periodontium. The Journal of Immunology, 2015, 195: 2231–2240.
P
eriodontal disease is one of the most common infectious
inflammatory diseases. With.30% prevalence in the adult
population and ∼8% being severe cases (leading to a complete
loss of a dentition), the disease presents substantial economic burden
(1). The influence of periodontitis on systemic health and its likely
contribution to cardiovascular diseases, diabetes, as well as rheumatoid
arthritis (2–4) underscore a crucial role of inflammation in the disease
mechanism and emphasize the need of innovative and effective ther-
apies. Recent advances in understanding the molecular basis of inter-
action between periodontal pathogens and host innate immunity
system revealed a double-edged sword role of complement in chronic
inflammatory events driving periodontal tissue destruction (5).
Complement is produced in the body both locally and sys-
temically, and it provides the first arm of defense against pathogens.
This involves pattern-recognition molecules of the classical
pathway, that is, the C1 complex (composed of recognition mol-
ecule C1q and two proteinases C1s and C1r), and the lectin pathway,
that is, mannose-binding lectin (MBL)/ficolin complexes (composed
of MBL or ficolins and three MBL-associated proteinases MASP-1,
MASP-2, and MASP-3). These molecules ensure efficient recogni-
tion of the invading pathogen with subsequent activation of the
complement cascade. Additionally, complement can be activated on
microbial or non-self surfaces, which lack complement inhibitors,
through the alternative pathway, based on the constant low level of
spontaneous hydrolysis of C3 to C3(H2O). The latter is further sta-
bilized in the presence of factors B and D into alternative pathway C3
convertase, providing substantial amplification loop, accounting for
$80% of the total complement activation (6). All three pathways
lead to opsonization of the pathogen with C3b (an activated form of
complement factor C3), which facilitates phagocytosis. Furthermore,
anaphylatoxins released during activation of the cascade, C3a and
C5a, stimulate inflammatory cells and attract phagocytes to the site of
infection by involvement of specific G-coupled receptors C3a re-
ceptor (C3aR) and C5a receptor (C5aR), respectively. Finally, the end
result of the complement cascade is formation of the membrane at-
tack complex (MAC) and bacterial cell lysis. Expression of
membrane-bound as well as recruitment of soluble complement
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inhibitors provides the protection for the host cells when this powerful
system is activated. Unfortunately, this sophisticated system is often
corrupted by microbial pathogen–derived proteinases (7), which in the
case of periodontitis may contribute to tissue damage by chronic in-
flammation driven by subgingival plaque bacteria.
It has been long recognized that chronic periodontitis is an infec-
tious disease; however, no single bacterial species has been identified
as “etiologic” for progression of the disease. Several bacterial clusters
within a complex periodontal biofilm have been described, with three
major consensus periodontal pathogens composing the so-called
“red complex”: Tannerella forsythia, Porphyromonas gingivalis, and
Treponema denticola (8). Recent advancement in periodontal studies
finally refuted the perception of periodontitis as a classical infection,
triggered by a single or limited number of microorganisms. Rather,
periodontal disease is the result of dysbiosis in the oral microbiota,
leading to the formation of pathogenic biofilm of altered composition
and increased bacterial counts, which, in turn, causes complement-
dependent inflammation of periodontium and consequently bone loss
(9, 10). In contrast to the previous hypothesis implicating a crucial
contribution of red complex species in the pathogenesis of peri-
odontal disease, the new model of polymicrobial synergy and dys-
biosis proposes a concept of low-abundant keystone pathogens
capable of breaking down periodontal homeostasis and changing
normal benign oral biofilm into a dysbiotic one (9). This novel
concept was introduced based on the findings involving the most
intensively studied prototype periodontal pathogen P. gingivalis (11).
To disrupt host homeostasis and induce dysbiosis, this bacterium
engages two receptors: complement receptor C5aR, activated by
P. gingivalis–induced C5a, and TLR2. The resulting C5aR–TLR2
cross-talk impairs the killing functions of macrophages and neu-
trophils, alters the composition of oral biofilm, and leads to upregu-
lation of inflammatory and bone resorptive cytokines (11–14). These
studies changed the understanding of periodontal disease and left
open the question as to identification of other keystone pathogens. It
appears plausible that one important prerequisite of such a master
pathogen in periodontitis is the expression of a proteinase of C5
convertase activity, because P. gingivalis deficient in its C5a-releasing
proteinases, gingipains, did not induce dysbiosis in a mouse peri-
odontitis model (11). As we demonstrated before, P. gingivalis has
not one but three proteinases that can generate biologically active C5a
(15). T. forsythia, which is very important but so far a much less
studied component of the classical red complex, appears to be
equipped with proteinases of C5 convertase activity as well. We
previously showed that its metalloproteinase karilysin, among other
complement-targeting activities, can release C5a and induce migra-
tion of neutrophils (16). A recent study on T. forsythia revealed the
existence of an entire array of genes encoding putative secretory
proteinases with similarity to karilysin, all possessing a nearly iden-
tical C-terminal domain that ends with a -Lys-Leu-Ile-Lys-Lys motif.
These proteins, referred to as KLIKK proteinases, may function as
virulence factors (17). In the present study we characterize the role of
one of these, a novel metalloproteinase of T. forsythia, mirolysin
(Mir), of similar complement modulating functions as karilysin.
Furthermore, we provide evidence that mirolysin and karilysin act in
synergy and render T. forsythia resistant to serum bactericidal activity.
Materials and Methods
Ethics statement
The local Ethical Review Committee in Lund has approved collection of
sera from healthy human volunteers. The Ethical Committee of Jena
University approved collection of periodontal plaques and gingival crev-
icular fluid (GCF). Written informed consent was obtained from patients
and volunteers and the investigation was performed according to principles
of the Declaration of Helsinki.
Sera and proteins
Normal human serum (NHS) was obtained from eight healthy volunteers.
Heat-inactivated NHS was made by incubating NHS for 30 min at 56˚C.
Sera deficient in various complement components as well as matching
NHS were obtained from Quidel. Purified complement proteins C3, C4, and
C5 were purchased from Complement Technology. Mirolysin, cloned from the
T. forsythia ATCC 43037 genome, as well as its inactive mutant MirE341A (the
catalytic glutamic acid was replaced by alanine) were expressed as GST-tagged
recombinant proteins in E. coli and purified by affinity chromatography on
glutathione-Sepharose 4 Fast Flow (GE Healthcare). The GST tag was re-
moved from recombinant proteins bound to GSH-Sepharose by cleavage with
PreScission Protease (GE Healthcare). Tag-free mirolysin and inactive mutant
MirE341A were subsequently purified by size exclusion chromatography using
a Superdex 75 HiLoad 16/60 (Pharmacia Biotech) column. The metal-
loproteinase karilysin forms Kly48, high-molecular-mass karilysin (Kly38),
and low-molecular-mass karilysin (Kly18) were purified as described (16).
Interpain A (InpA) was expressed and purified as in Potempa et al. (18).
Abs
The following Abs against human Ags were used throughout this study:
polyclonal (pAbs) rabbit anti-C1q, C4c, and C3d Abs (all from Dako), goat
anti-MBL (R&D Systems), goat anti-C5 (Quidel), mAb mouse anti–
ficolin-2 (19) or anti-ficolin-3 (20), and mouse anti-C9 neoantigen Abs
(HyCult Biotech). Secondary pAbs conjugated with HRP against rabbit,
goat, or mouse were from Dako.
Bacterial strains and their culture
T. forsythia strain ATCC 43037 was grown on hemin N-acetylmuramic
acid vitamin K (HNK) agar plates at 37˚C in an anaerobic chamber
(Concept 400, Biotrace) with an atmosphere of 90% N2, 5% CO2, and
5% H2. The purity and correct identity of the cultures were confirmed by Gram
staining and 16S rDNA sequencing. T. forsythia mutant strains lacking
mirolysin (Dmir) or karilysin (Dkly) were grown similarly, with supple-
mentation of 10 mg/ml chloramphenicol or 5 mg/ml erythromycin in the
agar plates, respectively.
Construction of proteinase deletion mutants
Deletional inactivation of mir (BFO_2661; formerly known as T0341)
gene encoding mirolysin metalloproteinase in T. forsythia. The plasmid
for deletion of the mir gene (BFO_2661) was based on two synthesized
DNA fragments (GeneArt Strings, Life Technologies) and the pUC19
plasmid backbone. Each fragment contained a portion of 341 adjacent
genomic sequence and part of the chloramphenicol acetyltransferase (cat)
gene truncated in the vicinity of an internal EcoRI restriction site. The first
DNA fragment contained a 59 SacI restriction site, followed by a 778-bp
DNA fragment upstream of the BFO_2661 start codon followed by
a 221-bp DNA sequence encoding cat. The second DNA fragment con-
sisted of 449-bp of the cat gene, followed by 551-bp of a BFO_2661 39
untranslated region, terminated with a KpnI restriction site. The two DNA
fragments were ligated after EcoRI digestion and cloned into the SacI and
KpnI sites of pUC19. The correct orientation of the DNA fragments in the
plasmid was confirmed by sequencing.
Deletional inactivation of kly (BFO_2683; formerly known as T0367) gene
encoding karilysin metalloproteinase in T. forsythia. To obtain a plasmid
for kly (BFO_2683) deletion, an erythromycin cassette was flanked by two
DNA fragments amplified from T. forsythia genomic DNA. The upstream
972-bp fragment was amplified with primers 59-TGTGAATTCGAGC-
GAAGCGATGAATCTCCTC-39 and 59-GATCCCGGGCTGTAGTCGT-
CAAATGGGACG-39, containing sequences for EcoRI and SmaI, respectively.
The 1235-bp long downstream fragment was amplified with primers
59-GTAGTCGACGATTAAGAAGTGATGCCCTTCG-39 (containing a SalI
site) and 59-GCTCGCCATAGAAATAACAAGCTTAGA-39 (containing a
HindIII site). An erythromycin resistance cassette (ermF-ermAM) was am-
plified from plasmid pURgpB-E (21) with the following primers:
59-CTACCCGGGACAACGAATTATCTCCTTAA-39 (with a SmaI restriction
site) and 59-CTCGTCGACTTTTATTGCCAAGTTCTAATGC-39 (with a SalI
restriction site). All DNA fragments were digested by indicated restriction
enzymes and cloned into pUC19 digested with EcoRI and HindIII. The correct
placement of DNA fragments was confirmed by sequencing.
Electroporation of T. forsythia. Electrocompetent T. forsythia cells were
obtained by a modified procedure as described in Sakakibara et al. (22).
Briefly, cells from 5-d-old plates were collected to a 50-ml conical tube
and washed twice with 20 ml electroporation buffer (1 mM MgCl2, 10%
glycerol) and resuspended in 1 ml of the same buffer. One microgram
plasmid DNA was electroporated to 100 ml bacterial slurry in a Micro-
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Pulser electroporation apparatus (Bio-Rad Laboratories) (2.5 kV, 4 ms)
followed by incubation in growth medium for 12 h. Thereafter, bacteria
were collected and plated on selective media containing 10 mg/ml chlor-
amphenicol or 5 mg/ml erythromycin. Then, 8-d resistant clones were
subcultured and tested for correct cassette placement by sequencing.
Confirmation of correct gene deletion in T. forsythia. Genomic DNA from
the parental strain (ATCC 43037) and its mutants lacking mirolysin (Dmir)
and karilysin (Dkly) were isolated using a genomic DNA purification
kit (Thermo Scientfic). PCR amplification of genes BFO_2661 (mir),
BFO_2683 (kly), and a control gene BFO_2665 [encoding another KLIKK
proteinase mirolase, formerly known as TF0347 (17)] was performed with
primers listed in Table I. The PCR with Taq polymerase (Thermo Scien-
tific) was performed for 30 cycles consisting of denaturation at 95˚C for
30 s, annealing at 56˚C for 20 s, and polymerization at 72˚C for 30 s. The
amplified PCR products were then analyzed by electrophoresis on 2%
agarose gel.
Determination of mirolysin expression in vivo
Patients with diagnosed chronic periodontitis attending the Clinic of
Periodontology at the University Hospital of Jena were recruited for this
study. For detection of T. forsythia in clinical samples, GCF samples were
obtained from patients with severe periodontitis (aggressive periodontitis,
n = 17; chronic periodontitis, n = 37) and healthy controls (n = 6). Two
paper points were inserted in each pocket for 20 s and DNA was subse-
quently extracted using the Genomic Mini system (A&A Biotechnology)
according to the manufacturer’s recommendations. PCR for detection of
T. forsythia was carried out as described (23). To determine whether the
mirolysin gene (mir) was transcribed in vivo, part of GCF was kept frozen
at220˚C until mRNAwas extracted for RT-PCR analysis. Total RNA from
∼50 ml GCF was purified using an RNeasy kit (Qiagen), and cDNA was
synthesized from 1 mg total RNA using the Omniscript kit according to
the manufacturer’s instructions. Oligonucleotide primers (sense primer
59-CGAACATCGACTTCCACAGA-39 and anti-sense primer 59-TGTTTTA-
GGGAACGAAGGACA-39) were used at a final concentration of 5 pmol. The
PCR with Taq polymerase was performed for 30 cycles consisting of dena-
turation at 94˚C for 30 s, annealing at 56˚C for 25 s, and polymerization
at 72˚C for 30 s. The amplified PCR products were thereafter analyzed
by electrophoresis on 2% agarose gel.
MAC deposition on T. forsythia
T. forsythia was harvested, washed once in PBS, adjusted to OD600 of 0.6,
and incubated for 30 min with 5 mM CFSE (Sigma-Aldrich). After pre-
staining with CFSE, bacteria were washed once in GVB++ (5 mM veronal
buffer [pH 7.3], 140 mM NaCl, 0.1% gelatin, 1 mM MgCl2, and 5 mM
CaCl2) and adjusted to an OD600 of 0.6. Thereafter, 120 ml bacteria was
mixed with 10–40% NHS diluted in GVB++ and incubated anaerobically
for 30 min at 37˚C in a total volume of 200 ml. For DNHS, 40% was used
as a control. Thereafter bacteria were washed once in flow cytometry
buffer (50 mM HEPES, 100 mM NaCl [pH 7.4], 1% BSA, and 30 mM
NaN3) and incubated with specific mAb against C9 neoantigen, followed
by secondary pAbs conjugated with Alexa Fluor 647 (Life Technologies).
Finally, samples were washed twice, resuspended in fixing buffer (BD
Biosciences) diluted 1:10 in H2O, and analyzed using flow cytometry
(CyFlow space, Partec, Munster, Germany). The geometric mean fluo-
rescence intensity for 10,000 CFSE+ cells was calculated for all the
samples using FlowJo software (Tree Star).
Bactericidal assay
T. forsythia strain ATCC 43037 and its mutants Dkly and Dmir were har-
vested from agar plates, washed once in GVB++, and adjusted to an OD600
of 0.01. Thereafter, 10 ml (∼3 3 105 bacteria) were mixed anaerobically
with 10 and 30% NHS or, as control, 30% DNHS diluted in GVB++, in
a total volume of 100 ml. The samples were incubated anaerobically at 37˚C
for 40 min with shaking. After incubation, aliquots were removed, serially
diluted, and spread on appropriate agar plates. Plates were incubated in an
anaerobic chamber for 7–10 d and the survival at different conditions was
calculated as percentage of input CFU for each strain. Resupplementation
experiments of knockout strains with recombinant proteinases were performed
with only small modifications. Briefly, 90 ml NHS (7.5%) diluted in 50 mM
HEPES (pH 7.4), 150 mM NaCl, 2 mM MgCl2, and 5 mM CaCl2 was pre-
incubated for 30 min at 37˚C with recombinant Mir or Kly38, after which
10 ml relevant knockout bacteria were added. The samples were further in-
cubated for 30 min and processed as above.
Hemolytic assays
To assess activity of the classical pathway, sheep erythrocyteswerewashed three
times with DGVB++ buffer (2.5 mM veronal buffer [pH 7.3], 70 mM NaCl,
140 mM glucose, 0.1% gelatin, 1 mM MgCl2, and 5 mM CaCl2). The cells
were incubated with a complement-fixing Ab (Amboceptor from Behring-
werke, diluted 1:3000 in DGVB++ buffer) at a concentration of 109 cells/ml for
20 min at 37˚C. After two washes with DGVB++, 5 3 108 cells/ml were in-
cubated for 1 h at 37˚C with 0.3% NHS diluted in DGVB++ buffer (total
volume 150 ml). Before incubation with erythrocytes, NHS was preincubated
with various concentrations of mirolysin for 15 min at 37˚C. The samples were
centrifuged and the amount of lysed erythrocytes was determined by spec-
trophotometric measurement of the amount of released hemoglobin (405 nm;
Varian 50 MPR microplate reader).
To assess activity of the alternative pathway, rabbit erythrocytes were
washed three times with GVB++ buffer and then used at a concentration of
5 3 108 cells/ml for 1 h incubation at 37˚C with 3% C1q-depleted human
serum (Quidel) diluted in GVB++ buffer (total volume 150 ml). The serum
used was pretreated with mirolysin variants for 25 min at 37˚C. The
samples were centrifuged and the amount of lysed erythrocytes was de-
termined spectrophotometrically (405 nm; Varian 50 MPR microplate
reader).
Complement activation assays
Microtiter plates (MaxiSorp, Nunc) were incubated overnight at 4˚C with
50 ml of a solution containing 2 mg/ml human aggregated IgG (Immuno),
100 mg/ml mannan (Sigma-Aldrich, M-7504), and 20 mg/ml zymosan
(Sigma-Aldrich, Z-4250) in 75 mM sodium carbonate (pH 9.6) or 10 mg/ml
acetylated BSA (Sigma-Aldrich, acetylated as described in Ref. 24) in PBS.
Between each step of the procedure, the plates were washed four times with
50 mM Tris-HCl, 150 mMNaCl, and 0.1% Tween 20 (pH 7.5). The wells were
blocked with 1% BSA (Saveen Werner) in PBS for 2 h at room temperature.
NHS (classical and lectin pathways) was diluted in GVB++ buffer and used at
a concentration of 2% for measurement of deposition of C1q, 1% for C3b and
C4b in the classical pathway, 2% for C3b, C4b, ficolin-2, and ficolin-3 in the
lectin pathway, and 4% for MBL. In the case of the alternative pathway, C1q-
depleted serum was used at a concentration of 4% for both C3b and C5b.
These concentrations were chosen on the basis of initial titrations. The serum
used was mixed with various concentrations of mirolysin variants, pre-
incubated for 25 min at 37˚C, and incubated in the wells of microtiter plates for
45 min at 37˚C for C1q, MBL, ficolin-2, and ficolin-3, 30 min at 37˚C for C3b
and C4b (classical and lectin pathways), and 35 min for C3b and C5 (alter-
native pathway). Complement activation was assessed by detecting de-
posited complement factors using specific Abs against C1q, C4b, C3d,
C5, MBL, ficolin-2, and ficolin-3 diluted in the blocking buffer. Bound
Abs were detected with HRP-labeled anti-rabbit, anti-goat, or anti-mouse
secondary pAbs. Bound HRP-labeled pAbs were detected with 1,2-
phenylenediamine dihydrochloride tablets (Dako), with absorbance
measured at 490 nm.
Degradation assay
C3, C4, and C5 (0.1 mM each) diluted in 50 mM HEPES, 75 mM NaCl,
and 5 mM CaCl2 (pH 7.4) were incubated with Mir at concentrations
ranging from 0.06 to 2 mM Mir or 2 mM MirE341A alone for 1 h at 37˚C.
Table I. Primers for PCR confirming deletional inactivation of mir and kly
Gene Primers
BFO_2661 (mir) Forward 59-GTTAATTCAGCCCAATGCGAA-39
Reverse 59-GTGAATTCCGGATGAGCATTC-39
BFO_2683 (kly) Forward 59-GGCAATGCTTCGTAAGATTTTCC-39
Reverse 59-CCGTTACTTATGAGCAAGTATTGTC-39
BFO_2665 (KLIKK proteinase, mirolase) Forward 59-GAATACATCCGTAAGAGTAGCGG-39
Reverse 59-AGGGCTGTCATTGTCGTTCGG-39
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The proteins were separated by SDS-PAGE electrophoresis using the
standard Laemmli procedure and 12% gels. Prior to electrophoresis the
samples were boiled for 5 min at 95˚C in a reducing sample loading buffer
containing 25 mM DTT and 4% SDS. After separation, the gels were
stained with silver salts to visualize separated proteins.
Chemotaxis assay
For C5a chemotaxis assays, plasmawas used, as serummay contain C5a and
C5a des-Arg produced during blood coagulation (25). Human neutrophils
were isolated as described (26), stained with 1 mM CFSE, washed, and sus-
pended in 4% solution of heat-inactivated human plasma (30 min, 56˚C) to the
final concentration of 5 3 106 cells/ml. Chemotactic activity was measured in
a disposable 96-well cell migration system with 3-mm polycarbonate mem-
branes (ChemoTx, Neuro Probe). Serial dilutions of Mir and its inactive mutant
MirE341Awere incubated with 4% heat-inactivated human plasma (the same as
for neutrophil suspensions) for 25 min at 37˚C and thereafter applied to the
wells of a ChemoTx microplate. Plasma-purified human C5a (Complement
Technology) diluted in 4% heat-inactivated human plasma served as a positive
control whereas 2 mM Mir and MirE341A in PBS and PBS alone were used as
negative controls. A volume of 50 ml neutrophil suspension was applied on
each well of the filter top. The microplate was incubated for 60 min at 37˚C in
humidified air with 5% CO2, and then the membrane was removed. Samples
were transferred to the new flat-bottom black 96-well plates (Nunc) and the
emptied wells were washed twice with 30 ml PBS, with subsequent pooling of
washes with the respective samples (final volume 90 ml). Fluorescence at 535
nm was collected using Wallac 1420 Victor2 microplate reader (PerkinElmer).
Statistical analysis
One-way or two-away ANOVA (GraphPad Prism) was used to calculate the
p values to estimate whether the observed differences between experi-
mental results were statistically significant.
Results
The gene mir encoding mirolysin is commonly present in
T. forsythia
Given the pivotal role of periodontal bacteria proteinases to the
pathogenic mechanism of periodontitis via modulating complement
activity, we sought to determine the expression of novel proteinases by
a series of T. forsythia strains. Previously, we demonstrated a key role
of a metalloproteinase karilysin of T. forsythia in the defense against
complement (16). The sequenced genome of T. forsythia ATCC
43037 (available at: http://www.ncbi.nlm.nih.gov/gene/) contains
several putative proteinases, which share a unique multidomain
structure with karilysin and contain characteristic C-terminal domains
ending with 5-aa residues (Lys-Leu-Ile-Lys-Lys), for which they were
collectively named KLIKK proteinases. One of the KLIKK protei-
nases, a metalloproteinase of the M43 family of proteolytic enzymes,
is encoded by the gene BFO_2661. This novel metalloproteinase
named mirolysin was cloned from the T. forsythia ATCC 43037
genome. To evaluate its relevance in vivo, we investigated the pres-
ence of mir in clinical isolates of T. forsythia by performing PCR on
GCF samples of patients with periodontitis and on healthy controls.
Most patients with both chronic and aggressive periodontitis carried
T. forsythia strains (evidenced by the presence of T. forsythia–specific
DNA; Table II), of which .80% expressed mir gene. To prove that
the mir gene was also transcribed in vivo, we analyzed GCF samples
isolated from patients with periodontitis by RT-PCR and found that
all analyzed samples containing the mir gene were positive for mir
mRNA as well (Fig. 1A, Table II). The pattern of expression of mir in
T. forsythia strains appeared to correlate with kly mRNA expression,
which we analyzed in our previous study (16).
Mirolysin contributes to serum resistance of T. forsythia strains
and appears to exert a synergistic effect in combination with
karilysin
To further prove the role of both mirolysin and karilysin in
complement evasion of T. forsythia, we generated single knockout
strains of these proteinases and confirmed deletional inactivation
of respective genes by PCR (Fig. 1B). Next, we tested the ability
of these strains to resist complement attack. Strikingly, both
knockout strains Dkly and Dmir showed increased deposition of
the terminal complement product, MAC (Fig. 1C), compared with
their parental strain. Increased complement attack of bacterial
strains devoid of single metalloproteinases translated into their
largely abolished survival in human serum (Fig. 1D). Whereas
the parental strain proliferated equally well in NHS and heat-
inactivated NHS, both mutants showed diminished growth in
10% NHS and were completely eradicated in 30% NHS (Fig. 1D).
These results clearly indicate that both karilysin as well as mir-
olysin play a major role in complement evasion by T. forsythia.
Furthermore, to restore the phenotype of knockout strains, we
supplemented these with recombinant proteinases and incubated
them with 7.5% NHS. For Dmir, already as low as 0.6 mM
recombinant enzyme was sufficient to provide protection against
complement, and at higher concentrations of the enzyme, the
knockout strain reached proliferation ability of the parental bac-
teria (Fig. 1E). An analogical experiment performed for Dkly
yielded similar results (Fig. 1F).
Mirolysin interferes with classical and alternative complement
pathways
To find out how the novel metalloproteinase mirolysin can con-
tribute to complement-modulating ability of T. forsythia, we tested
its activity in well-established hemolytic assays. The enzyme was
incubated at various concentrations with human serum, and the
hemolytic activity of the classical and alternative pathways of
complement was analyzed in the pretreated sera. Mirolysin exerted
dramatic inhibition of classical pathway–mediated hemolysis, in
contrast to its inactive mutant MirE341A, which had no effect
(Fig. 2A). Next, we used a modified hemolytic assay to test the
activity in the alternative pathway, as mirolysin requires calcium
ions for activity whereas the standard buffer used for the alter-
native pathway assay contains EGTA, which chelates calcium.
Therefore, GVB++ buffer and C1q-depleted NHS were used for
incubation with rabbit erythrocytes. Under such conditions, Mir
strongly inhibited the alternative pathway (Fig. 2B) whereas the
inactive mutant MirE341A had no effect.
Mirolysin inhibits classical pathway at the level of C4
The triggering of complement takes place via distinct cascade
pathways (classical, lectin, or alternative), which proceed in
a consecutive manner and converge at the level of C3 activation. To
assess which stages of complement pathways were affected by
Table II. Prevalence of T. forsythia and the presence of mirolysin in subgingival plaque samples
Group (n) Prevalence of T. forsythia
Mirolysin Gene Presence in
T. forsythia–Positive Samples
Healthy controls (6) 1/6 (17%) 0/1 (0%)
Aggressive periodontitis (17) 15/17 (88%) 13/15 (87%)
Chronic periodontitis (37) 28/37 (76%) 24/28 (86%)
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mirolysin, a microtiter plate–based assay was used. In this assay,
complement activation was initiated by various ligands, depending
on the activation pathway analyzed, and the deposition of suc-
cessive complement factors was then detected with specific Abs.
In the case of the classical pathway, complement activation was
initiated by aggregated human Igs. We found that deposition of
C1q on aggregated IgG was not inhibited, but rather increased in
the presence of mirolysin (up to 320%; Fig. 3A). However, sub-
sequent deposition of C4b (Fig. 3B) and C3b (Fig. 3C) was
inhibited by mirolysin, indicating its effect on C4 level. The in-
active MirE136A mutant was devoid of any activity on the classical
pathway (Fig. 3A–C). Additionally, when human serum was
preincubated with mirolysin in the absence of any immobilized C1
activator and added to empty microtiter plate blocked with BSA,
we detected increasing C1q deposition on this inert surface with
increasing Mir concentration, whereas there was no C1q deposi-
tion from NHS alone. This effect was not observed for the inactive
mutant MirE341A (Fig. 3D).
Mirolysin interferes with the lectin pathway at the level of
MBL, ficolin-2, and ficolin-3
For assessment of the lectin pathway, we used plates coated with
mannan (ligand for MBL) or acetylated BSA (ligand for ficolins).
Deposition of the lectin pathway recognition molecules ficolin-2
(Fig. 4A), ficolin-3 (Fig. 4B), and MBL (Fig. 4C) was inhibited
by mirolysin, followed by inhibition of the ensuing factors such as
C4b (Fig. 4D) and C3b (Fig. 4E). The MirE341A mutant had no
effect (Fig. 4).
Mirolysin targets the terminal pathway at the level of C5
The alternative pathway was activated by immobilized zymosan in
GVB++ buffer and C1q-deficient serum. Whereas C3b deposition
was not affected by Mir (Fig. 5A), the deposition of C5b was
FIGURE 1. Mir is abundantly expressed by T. forsythia isolates and
contributes to their serum resistance. (A) Mirolysin expression in GCF
from patients with chronic periodontitis. Mirolysin-specific mRNA was
amplified by RT-PCR and separated on agarose gel. Lanes 1–5, GCF
samples from five representative patients carrying T. forsythia and mir-
olysin gene. (B) PCR confirmation of mirolysin and karilysin deletion in
the laboratory strain of T. forsythia. Genomic DNAwas isolated from WT
bacteria or proteinase knockout strains deficient in mirolysin (Dmir)
or karilysin (Dkly). PCR was performed with mir-specific primers
(BFO_2661), kly-specific primers (BFO_2683), or control proteinase
(mirolase) gene-specific primers (BFO_2665). (C) T. forsythia strains were
incubated for 30 min with several concentrations of NHS or high con-
centration of ΔNHS diluted in GVB++. Deposited MAC was detected with
specific Abs using flow cytometry. Deposition of MAC is shown as geometric
mean fluorescence intensity and means of three independent experiments are
presented with bars indicating SD. (D) T. forsythia strains were incubated
for 40 min with NHS or ΔNHS. (E and F) NHS was preincubated with
recombinant Mir (E) or Kly38 (F) for 30 min, added to relevant knockout
strains, and incubated for another 30 min. In (D)–(F), the survival of bacteria
was calculated as a percentage of growth compared with the inoculum (input
CFU). In (C) and (D), statistical significance of observed differences between
T. forsythia strains was estimated using two-way ANOVA and a Bonferroni
posttest. *p, 0.05, **p, 0.01, ***p, 0.001, NS when nothing is indicated.
In (E) and (F), statistical significance of observed differences was estimated
using one-way ANOVA and a Dunnett posttest. **p , 0.01, ***p , 0.001
calculated compared with 0 mM proteinase. M, DNA size maker; NC, negative
control in which reverse transcriptase was omitted; PC, positive control, that is,
RNA isolated from cultured T. forsythia.
FIGURE 2. Mirolysin destroys hemolytic activity of human serum. (A)
Classical pathway. NHS (0.3%) was supplemented with various concen-
trations of mirolysin or the inactive mutant and preincubated for 15 min at
37˚C, after which sheep erythrocytes sensitized with Abs and diluted in
DGVB++ were added. (B) Alternative pathway. C1q-depleted human serum
(3%) was preincubated with increasing concentrations of mirolysin or the
inactive mutant for 25 min at 37˚C. Serum was then added to sheep
erythrocytes diluted in GVB++. For both (A) and (B), after 1 h incubation,
the degree of lysis was estimated by measurement of released hemoglobin
(absorbance at 405 nm). Lysis obtained in the absence of mirolysin was set
as 100%. In (A) and (B), an average of three independent experiments is
presented with bars indicating SD. Statistical significance of observed
differences was estimated using two-way ANOVA and a Bonferroni
posttest. *p , 0.05, **p , 0.01, ***p , 0.001.
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inhibited (Fig. 5B), indicating that the early stages of alternative
pathway activation are not targeted by this metalloproteinase, but
the common terminal pathway is inhibited. The inactive mutant
MirE341A had no effect on C3b or C5b deposition (Fig. 5).
Mirolysin cleaves preferentially a2chains of C3, C4, and C5
and generates biologically active C5a
As observed in our previous studies on periodontal proteinases,
these enzymes preferentially target a-chains of major complement
factors C3, C4, and C5 (15, 16, 18). To verify whether this was the
case for mirolysin, we incubated purified complement factors C3,
C4, and C5 with different concentrations of Mir. The proteins
were then separated by SDS-PAGE and visualized using silver
staining (Fig. 6A–C). C4 is composed of covalently linked a-, b-,
and g-chains whereas C3 and C5 contain a- and b-chains. For all
these proteins, mirolysin first proteolytically cleaved the a-chain
whereas the b-chains and g-chain of C4 were relatively resistant.
FIGURE 3. Mirolysin inhibits the classical pathway of complement.
Mirolysin was incubated for 25 min with 2% (C1q) or 1% (C3b, C4b) NHS
diluted in GVB++ and added to microtiter plates coated with IgGs. After
20 min (C3b, C4b) and 45 min (C1q) of incubation, the plates were washed
and deposited C1q (A), C4b (B), and C3b (C) were detected with specific
pAbs. (D) Empty microtiter plates were blocked with BSA and incubated
for 45 min with 5% NHS containing various concentrations of proteinases.
Deposited C1q was detected with a specific Ab. Absorbance from wells
containing NHS in the absence of mirolysin was set as 100%. An average
of three independent experiments is presented with bars indicating SD.
Statistical significance of observed differences was estimated using two-
way ANOVA and a Bonferroni posttest. *p , 0.05, ***p , 0.001.
FIGURE 4. Mirolysin inhibits the lectin pathway of complement. Mirolysin
was incubated for 25 min with 4% (MBL) or 2% (C3b, C4b, ficolin-2, ficolin-3)
NHS diluted in GVB++ and added to microtiter plates coated with mannan
(MBL, C3b, and C4b) or acetylated BSA (ficolins). After 20 min (C3b, C4b)
or 45 min (MBL, ficolin-2, ficolin-3) of incubation, the plates were washed and
deposited ficolin-2 (A), ficolin-3 (B), MBL (C), C4b (D), and C3b (E) were
detected with specific pAbs. Absorbance obtained in the absence of
mirolysin was set as 100%. An average of three independent experiments
is presented with bars indicating SD. Statistical significance of observed
differences was estimated using two-way ANOVA and a Bonferroni
posttest. **p , 0.01, ***p , 0.001.
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The degradation of C3 was very limited, with little truncation of
the a-chain that did not appear to be processed further (Fig. 6A).
In case of a-chains of C4 and C5, the cleavage by Mir was very
efficient, as even at the lowest enzyme concentration there was
a clear effect of the proteinase (Fig. 6B, 6C). The inactive mutant
did not cause any degradation of C3, C4 or C5 (Fig. 6A–C). Of
note, mirolysin is susceptible to autocatalytic processing during
incubation, hence the presence of two bands on SDS-PAGE.
The cleavage of C5 by mirolysin indicated that the proteinase
produced a pattern potentially corresponding to C5b (truncated
a-chain and unprocessed b-chain) (Fig. 6C). At higher concentrations
of the enzyme, C5b was degraded further, because the truncated
a-chain was degraded completely, whereas b-chains became slightly
reduced in intensity. C5b generation under physiological conditions is
always accompanied by a release of small chemotactic peptide C5a
from C5 a-chain. Therefore we assessed whether incubation of pu-
rified protein with heat-inactivated human plasma would indeed result
in generation of functional chemotactic peptide C5a. Such a phe-
nomenon has previously been shown with karilysin or gingipains (15,
16). To this end, heat-inactivated human plasma was incubated with
several concentrations of Mir and MirE341A and then applied to lower
wells of a ChemoTx plate. Freshly purified human neutrophils were
allowed to migrate through the filter toward the samples containing
mirolysin-treated plasma. C5a served as a positive control. Mirolysin
stimulated neutrophil migration in a dose-dependent manner, with
chemotactic activity peaking at 0.75 mMMir, for which the achieved
migration was comparable to that toward 12.5 nM C5a (Fig. 6D). The
inactive mutant MirE136A did not generate chemotactic activity in
plasma. At the highest concentration Mir had no effect on neutrophil
migration, most probably owing to generation of an excessive amount
of C5a that desensitizes C5aR, causing a decrease of chemotactic
activity to the level comparable to that toward 125 nM C5a. In par-
allel to PBS, neither Mir nor MirE341A (2 mM) showed any chemo-
tactic activity when used alone (not shown).
T. forsythia mirolysin acts synergistically with karilysin, as
well as with InpA, a cysteine proteinase of Prevotella
intermedia
Karilysin and mirolysin are expressed together at similar levels by
T. forsythia in GCF (Fig. 1A). Therefore, we can assume that they
FIGURE 5. Mirolysin inhibits the alternative pathway of complement.
Mirolysin was incubated for 25 min with 4% C1q-depleted serum diluted
in GVB++ and added to microtiter plates coated with zymosan. After
30 min of incubation, the plates were washed and deposited C3b (A) or
C5b (B) was detected with specific pAbs. Absorbance obtained in the
absence of mirolysin was set as 100%. An average of three independent
experiments is presented with bars indicating SD. Statistical significance
of observed differences was estimated using two-way ANOVA and a
Bonferroni posttest. ***p , 0.001.
FIGURE 6. Mirolysin degrades preferentially a-chains of C3, C4, and
C5 and generates biologically active C5a. C3 (A), C4 (B), and C5 (C)
(0.2 mM each) were incubated with increasing concentrations of mirolysin
or 2 mM MirE341A. Incubations were carried out for 1 h and the proteins
were then separated by SDS-PAGE electrophoresis. The gels were stained
with silver salts. (D) Increasing concentrations of mirolysin or MirE341A
were incubated with 4% heat-inactivated human plasma and then placed in the
wells of a ChemoTx microplate. Fluorescence at 485 nm corresponding to the
number of CFSE-stained neutrophils that migrated through the membrane was
measured after 1 h incubation. PBS was used as negative control, and human
C5a (12 and 125 nM) was used as a positive control. Fluorescence obtained for
the highest migration in the assay (achieved for 12 nM C5a) was set as 100%.
An average of four independent experiments is presented with bars indicating
SD. Statistical significance of observed differences was estimated using one-
way ANOVA and a Dunnett posttest. **p , 0.01 and calculated compared
with untreated plasma (0 mM proteinase).
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would be found together at the sites of infection. Additionally,
owing to coaggregation and strict correlation of major periodontal
bacteria, it is also likely that proteinases of other periodontal
bacteria are secreted at similar sites as mirolysin. Hence, we
evaluated how they act on complement when incubated in com-
binations. To this end, Mir and the three karilysin forms (Kly48,
Kly38, and Kly18), as well as cysteine proteinases of P. gingivalis
(gingipains: HRgpA and RgpB are arginine-specific gingipains
whereas Kgp is lysine-specific) and P. intermedia (InpA), were
preincubated with 2% NHS at concentrations chosen to affect the
activity of the lectin pathway by only 10–30%. The deposition of
C3b was assessed. There was no synergy of mirolysin with any of
the gingipains, for which the combined effect was at most additive
(data not shown). In contrast, we found that all forms of karilysin
acted synergistically with mirolysin, because the deposition of
C3b in the presence of combinations of mirolysin and Kly48/
Kly38/Kly18 was lower than predicted if the effects of the pro-
teinases were added separately (Fig. 7). The same was observed
for the combination of mirolysin with InpA.
Discussion
Numerous studies addressing interactions of oral bacteria with
immune defenses have increased our understanding of the path-
ogenesis of periodontal disease. It has become evident that the
attempts to identify a single bacterial species etiologic for this
disease will likely never be successful owing to complexity of both
bacterial as well as host factors shaping the final homeostastic state
in the gingival crevice. At health, homeostasis in periodontal tissues
is maintained by a controlled low-grade inflammatory state, con-
fining the bacterial plaque to the gingival margin and keeping
limited flow of GCF, substantial to supply the periodontium with
essential nutrients (27). Along with the nutrients, various plasma
components are extruded to the gingival crevice, including com-
plement proteins, which increase in their concentrations once
bacterial biofilm manages to proliferate (e.g., during poor oral
hygiene) and spreads down to the crevice. At the inflammatory
conditions complement is found at 70–80% of its serum concen-
tration, with elevation of certain components reflecting their local
production (28, 29). Although complement is a key host defense
against pathogens, its activation must be tightly controlled because
when deregulated, it may excessively amplify inflammation and
contribute to immunopathology. Periodontal bacteria disrupt the
fine balance between complement activation and inhibition in the
periodontium, and they cause a shift toward exacerbated chronic
inflammation. In turn, this results in a dysbiosis of the whole oral
plaque in both composition and numbers, presumably due to the
overgrowth of those species that are better adapted to inflamma-
tory conditions (9, 30).
Bacterial proteinases targeting complement appear to be hall-
mark factors of successful periodontal pathogens. In this regard, it
has been shown that in contrast to a gingipains-deficient strain,
wild-type P. gingivalis can impair host defenses, avoid immune
clearance, and induce development of pathogenic oral plaque,
which then causes destruction of affected periodontal tissues (11,
12) However, the aforementioned results were obtained in mouse
models in the absence of other key pathogens strictly associated
with periodontitis normally simultaneously found in humans.
Given the polymicrobial nature of this disease, identification of
virulence mechanisms contributing to disruption of immune ho-
meostasis shared by different key periodontal pathogens could give
rationale for developing effective therapies. All three microorganisms
of the classical red complex strongly associated with periodontitis
exhibit similar correlations with the prevalence and severity of the
disease (8, 31). In this study, we provide evidence that T. forsythia
expresses virulence factors that allow it to modulate complement, and
in particular exploit the C5a/C5aR axis, the importance of which has
been recently highlighted in the pathogenesis of periodontitis (13,
32). Its metalloproteinase mirolysin appears to act synergisitically
with previously described karilysin (16) and exert biphasic effect on
complement. The prevalence of mirolysin in T. forsythia strains is
very high (Table II) and similar to that of karilysin. Mirolysin, similar
to karilysin, inhibits deposition of members of collagen-containing
lectin family of proteins, MBL and ficolins on mannan-coated sur-
faces (Fig. 4). The lectin pathway of complement allows recognition
of pathogens in the absence of specific Abs via direct binding of
MBL and ficolins to their surface carbohydrates. T. forsythia exposes
a whole array of carbohydrate moieties in glycans attached to its cell
surface layer (S-layer) (33). Hence, mirolysin together with karilysin
can help the bacterium to avoid this pathway, both at the stage of
recognition, but also downstream by targeting C4 (Fig. 3). In the case
of the classical pathway, C1q deposition from serum was enhanced in
the presence of mirolysin, both on aggregated IgG (Fig. 3A), but also
on a nonactivating surface coated with BSA (Fig. 3D). However,
downstream from this step, we observed inhibition of the classical
pathway at the level of C4. Induction of C1q deposition on inert
surfaces or bacterial surfaces was demonstrated before for other
periodontal bacterial proteinases, gingipains of P. gingivalis, and
InpA of P. intermedia (15, 18). However, whereas this effect could be
recreated in vitro using purified C1 for gingipains (15), InpA required
serum to be present for this to occur (18). In the case of mirolysin,
C1q deposition on BSA-coated plates occurred only in the presence
of NHS, but not for C1 alone (data not shown), similar to InpA. Thus,
it appears that mirolysin may require a third protein/serum factor to
induce C1 deposition. Furthermore, mirolysin does not cleave C1q
(data not shown), further indicating that its effect is not direct. These
data collectively show that periodontal pathogens have a versatile
influence on C1/C1q. Whereas benefits of limiting C1q deposition
appear obvious, one potential advantage of increased C1q deposition
would be when this effect could selectively be targeted on the
FIGURE 7. Mirolysin acts synergistically with karilysin of T. forsythia
as well as InpA of P. intermedia. Mannan was immobilized on microtiter
plates and allowed to activate 2% NHS containing 0.3 mM Mir, three
karilysin forms Kly48 (0.4 mM), Kly38 (0.4 mM), Kly18 (0.8 mM), and
InpA (0.3 mM), alone or mixed together. After 25 min of incubation, the
plates were washed and deposited C3b was detected with specific Abs. An
average of three independent experiments is presented with bars indicating
SD. Statistical significance of observed differences was estimated using
one-way ANOVA and a Tukey posttest. ***p , 0.001.
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surfaces of certain commensal oral bacteria. This could po-
tentially lead to the eradication of some complement-sensitive species
and thus contribute to the dysbiosis of the plaque observed in the
disease. In this regard, we observed that aureolysin of Staphylococcus
aureus increases C1q opsonization of a commensal Staphylococcus
epidermidis while limiting C1q level on S. aureus (26)
Regarding alternative pathway, mirolysin, similar to karilysin,
did not affect C3b deposition occurring via this pathway (Fig. 5A),
but it targeted the initial step of terminal complement pathway,
efficiently limiting C5b deposition (Fig. 5B). Interestingly, both
mirolysin and previously described karilysin show high specificity
toward the a-chain of C5 and lead to the release of a chemotactic
peptide C5a (Fig. 7). Because these two metalloproteinases act
synergistically (Fig. 7), the presence of T. forsythia at the infection
site can lead to the local generation of high C5a levels. C5a is
a very active molecule, and in principle it can contribute to
periodontal tissue damage via several mechanisms, mainly in-
creased vasodilation and vascular permeability together with the
chemotactic recruitment of inflammatory cells, including neu-
trophils. Neutrophil accumulation in periodontal pockets and in-
filtrating the junctional epithelium is one of the hallmark features
of periodontitis, and these cells appear to be involved in the
immunopathogenesis of the disease (34, 35). Similarly to de-
regulated complement activation, deviations in neutrophil acti-
vity (both impaired or exacerbated activity and/or recruitment)
result in the disrupted homeostasis in the periodontium and
manifest in humans by various forms of periodontitis (35, 36).
Local production of C5a by bacterial proteinases could certainly
affect both the migration and the activity of neutrophils in the
gingival crevice. The impact of C5a on neutrophils is not
straightforward, as it strictly depends on the exact levels of the
anaphylatoxins. Whereas low levels of C5a induce neutrophil
chemotaxis and increase their antibacterial activity, the high levels
evoke their “immune paralysis” demonstrated by inhibited mi-
gration and diminished performance (37, 38). Hence, taking into
account synergistic action of several periodontal bacterial protei-
nases, there is a high probability for local generation of high C5a
levels that could corrupt neutrophils populating the periodontium.
Additionally, the bacteria can further shut down immune defenses
when bridging two signaling pathways, that is, TLRs and C5aR.
Induction of such a cross-talk between TLR2 and C5aR in human
and mouse neutrophils as well as mouse macrophages by P. gin-
givalis resulted in abolished intracellular killing of bacteria and
had a profound impact on the oral bacterial community in mice
(11, 13, 14). It remains to be elucidated whether such a subversive
cross-talk can occur in the presence of other periodontal bacteria.
However, identification of C5a convertase–like enzymes in other
long-recognized pathogens of human periodontitis, such as
T. forsythia, underscores the importance of this virulence mech-
anism. As C5a appears to act in favor for key periodontal patho-
gens and the bystander species, a new therapeutic concept
emerged aiming to counteract C5a signaling by implementing
C5aR antagonists in periodontitis (32). Future studies will soon
bring more evidence proving efficiency of such a treatment. Of
note, the existence of two proteinases inactivating complement in
a similar way stresses the importance of complement evasion by
T. forsythia. It also highlights that the described mechanisms are
very vital for the survival of this pathogen. Furthermore, since
knocking out just one proteinase in T. forsythia (Mir or Kly)
resulted in drastically diminished complement resistance of the
pathogen, we can hypothesize that these enzymes do act syner-
gistically and both are vital for the bacterium. Furthermore, put-
ting presented data into the context of other similar studies (15,
16, 18), proteinases of periodontal bacteria with their fine-tuned
effects on complement emerge to be key virulence factors of these
pathogens.
Disclosures
The authors have no financial conflicts of interest.
References
1. Brown, L. J., B. A. Johns, and T. P. Wall. 2002. The economics of periodontal
diseases. Periodontol. 2000 29: 223–234.
2. de Pablo, P., I. L. Chapple, C. D. Buckley, and T. Dietrich. 2009. Periodontitis in
systemic rheumatic diseases. Nat. Rev. Rheumatol. 5: 218–224.
3. Seymour, G. J., P. J. Ford, M. P. Cullinan, S. Leishman, M. J. West, and
K. Yamazaki. 2009. Infection or inflammation: the link between periodontal and
cardiovascular diseases. Future Cardiol. 5: 5–9.
4. Iacopino, A. M. 2001. Periodontitis and diabetes interrelationships: role of in-
flammation. Ann. Periodontol. 6: 125–137.
5. Hajishengallis, G. 2010. Complement and periodontitis. Biochem. Pharmacol.
80: 1992–2001.
6. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway
revisited. J. Cell. Mol. Med. 12: 1074–1084.
7. Potempa, M., and J. Potempa. 2012. Protease-dependent mechanisms of com-
plement evasion by bacterial pathogens. Biol. Chem. 393: 873–888.
8. Holt, S. C., and J. L. Ebersole. 2005. Porphyromonas gingivalis, Treponema
denticola, and Tannerella forsythia: the “red complex”, a prototype polybacterial
pathogenic consortium in periodontitis. Periodontol. 2000 38: 72–122.
9. Hajishengallis, G., and R. J. Lamont. 2012. Beyond the red complex and into
more complexity: the polymicrobial synergy and dysbiosis (PSD) model of
periodontal disease etiology. Mol. Oral Microbiol. 27: 409–419.
10. Hajishengallis, G., T. Abe, T. Maekawa, E. Hajishengallis, and J. D. Lambris.
2013. Role of complement in host-microbe homeostasis of the periodontium.
Semin. Immunol. 25: 65–72.
11. Hajishengallis, G., S. Liang, M. A. Payne, A. Hashim, R. Jotwani, M. A. Eskan,
M. L. McIntosh, A. Alsam, K. L. Kirkwood, J. D. Lambris, et al. 2011. Low-
abundance biofilm species orchestrates inflammatory periodontal disease
through the commensal microbiota and complement. Cell Host Microbe 10:
497–506.
12. Liang, S., J. L. Krauss, H. Domon, M. L. McIntosh, K. B. Hosur, H. Qu, F. Li,
A. Tzekou, J. D. Lambris, and G. Hajishengallis. 2011. The C5a receptor impairs
IL-12-dependent clearance of Porphyromonas gingivalis and is required for in-
duction of periodontal bone loss. J. Immunol. 186: 869–877.
13. Maekawa, T., J. L. Krauss, T. Abe, R. Jotwani, M. Triantafilou, K. Triantafilou,
A. Hashim, S. Hoch, M. A. Curtis, G. Nussbaum, et al. 2014. Porphyromonas
gingivalis manipulates complement and TLR signaling to uncouple bacterial
clearance from inflammation and promote dysbiosis. Cell Host Microbe 15: 768–
778.
14. Wang, M., J. L. Krauss, H. Domon, K. B. Hosur, S. Liang, P. Magotti,
M. Triantafilou, K. Triantafilou, J. D. Lambris, and G. Hajishengallis. 2010.
Microbial hijacking of complement-Toll-like receptor crosstalk. Sci. Signal. 3:
ra11.
15. Popadiak, K., J. Potempa, K. Riesbeck, and A. M. Blom. 2007. Biphasic effect of
gingipains from Porphyromonas gingivalis on the human complement system.
J. Immunol. 178: 7242–7250.
16. Jusko, M., J. Potempa, A. Y. Karim, M. Ksiazek, K. Riesbeck, P. Garred, S. Eick,
and A. M. Blom. 2012. A metalloproteinase karilysin present in the majority of
Tannerella forsythia isolates inhibits all pathways of the complement system.
J. Immunol. 188: 2338–2349.
17. Ksiazek, M., D. Mizgalska, S. Eick, I. B. Thøgersen, J. J. Enghild, and
J. Potempa. 2015. KLIKK proteases of Tannerella forsythia: putative virulence
factors with a unique domain structure. Front. Microbiol. 6: 312.
18. Potempa, M., J. Potempa, T. Kantyka, K. A. Nguyen, K. Wawrzonek,
S. P. Manandhar, K. Popadiak, K. Riesbeck, S. Eick, and A. M. Blom. 2009.
Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits comple-
ment by degrading complement factor C3. PLoS Pathog. 5: e1000316.
19. Munthe-Fog, L., T. Hummelshøj, B. E. Hansen, C. Koch, H. O. Madsen,
K. Skjødt, and P. Garred. 2007. The impact of FCN2 polymorphisms and hap-
lotypes on the Ficolin-2 serum levels. Scand. J. Immunol. 65: 383–392.
20. Munthe-Fog, L., T. Hummelshøj, Y. J. Ma, B. E. Hansen, C. Koch,
H. O. Madsen, K. Skjødt, and P. Garred. 2008. Characterization of a polymor-
phism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen)
deficiency state. Mol. Immunol. 45: 2660–2666.
21. Nguyen, K. A., J. Travis, and J. Potempa. 2007. Does the importance of the
C-terminal residues in the maturation of RgpB from Porphyromonas gingivalis
reveal a novel mechanism for protein export in a subgroup of Gram-negative
bacteria? J. Bacteriol. 189: 833–843.
22. Sakakibara, J., K. Nagano, Y. Murakami, N. Higuchi, H. Nakamura,
K. Shimozato, and F. Yoshimura. 2007. Loss of adherence ability to human
gingival epithelial cells in S-layer protein-deficient mutants of Tannerella for-
sythensis. Microbiology 153: 866–876.
23. Ashimoto, A., C. Chen, I. Bakker, and J. Slots. 1996. Polymerase chain reaction
detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis
and advanced periodontitis lesions. Oral Microbiol. Immunol. 11: 266–273.
24. Hein, E., C. Honore´, M. O. Skjoedt, L. Munthe-Fog, T. Hummelshøj, and
P. Garred. 2010. Functional analysis of Ficolin-3 mediated complement activa-
tion. PLoS One 5: e15443.
The Journal of Immunology 2239









25. Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker,
U. B. Br€uckner, B. Nilsson, F. Gebhard, J. D. Lambris, and M. Huber-Lang.
2010. Molecular intercommunication between the complement and coagulation
systems. J. Immunol. 185: 5628–5636.
26. Jusko, M., J. Potempa, T. Kantyka, E. Bielecka, H. K. Miller, M. Kalinska,
G. Dubin, P. Garred, L. N. Shaw, and A. M. Blom. 2014. Staphylococcal pro-
teases aid in evasion of the human complement system. J. Innate Immun. 6: 31–
46.
27. Delima, A. J., and T. E. Van Dyke. 2003. Origin and function of the cellular
components in gingival crevice fluid. Periodontol. 2000 31: 55–76.
28. Lally, E. T., W. P. McArthur, and P. C. Baehni. 1982. Biosynthesis of complement
components in chronically inflamed gingiva. J. Periodontal Res. 17: 257–262.
29. Schenkein, H. A., and R. J. Genco. 1977. Gingival fluid and serum in periodontal
diseases. II. Evidence for cleavage of complement components C3, C3 proac-
tivator (factor B) and C4 in gingival fluid. J. Periodontol. 48: 778–784.
30. Darveau, R. P. 2010. Periodontitis: a polymicrobial disruption of host homeo-
stasis. Nat. Rev. Microbiol. 8: 481–490.
31. Schlafer, S., B. Riep, A. L. Griffen, A. Petrich, J. H€ubner, M. Berning,
A. Friedmann, U. B. Go¨bel, and A. Moter. 2010. Filifactor alocis—involvement
in periodontal biofilms. BMC Microbiol. 10: 66.
32. Hajishengallis, G., and J. D. Lambris. 2013. Complement-targeted therapeutics
in periodontitis. Adv. Exp. Med. Biol. 735: 197–206.
33. Posch, G., M. Pabst, L. Brecker, F. Altmann, P. Messner, and C. Scha¨ffer. 2011.
Characterization and scope of S-layer protein O-glycosylation in Tannerella
forsythia. J. Biol. Chem. 286: 38714–38724.
34. Nussbaum, G., and L. Shapira. 2011. How has neutrophil research improved our
understanding of periodontal pathogenesis? J. Clin. Periodontol. 38(Suppl. 11):
49–59.
35. Ryder, M. I. 2010. Comparison of neutrophil functions in aggressive and chronic
periodontitis. Periodontol. 2000 53: 124–137.
36. Hajishengallis, E., and G. Hajishengallis. 2014. Neutrophil homeostasis and
periodontal health in children and adults. J. Dent. Res. 93: 231–237.
37. Guo, R. F., N. C. Riedemann, K. D. Bernacki, V. J. Sarma, I. J. Laudes,
J. S. Reuben, E. M. Younkin, T. A. Neff, J. D. Paulauskis, F. S. Zetoune, and
P. A. Ward. 2003. Neutrophil C5a receptor and the outcome in a rat model of
sepsis. FASEB J. 17: 1889–1891.
38. Riedemann, N. C., R. F. Guo, K. D. Bernacki, J. S. Reuben, I. J. Laudes,
T. A. Neff, H. Gao, C. Speyer, V. J. Sarma, F. S. Zetoune, and P. A. Ward. 2003.
Regulation by C5a of neutrophil activation during sepsis. Immunity 19: 193–202.
2240 MIROLYSIN INHIBITS THE COMPLEMENT SYSTEM
 by guest on January 31, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
